ABUS as of Nov 4 · 04:04 ET

ABUSNasdaqPharmaceutical Preparations

Arbutus Biopharma Corp · Brief

Next report

8 days

Nov 12 · before openest.Q3 FY26

Earnings

Expected move

Inputs

±11.8%implied · report alone

3.424.34

straddle ±15.3%

spot 3.88exp Nov 20ATM strike 4ATM straddle 0.70IV 103%

Nov 3 closereport share · term structure

Expected move

Inputs

Implied vs realized

8 reportsHistory

0 of 7≥ implied

avg implied: ±17.3%
avg realized: ±2.4%

Jan 13 '25±7.5%▲+1.82%×0.24

Mar 27 '25±43.7%▼−2.39%×0.05

May 14 '25±14.1%▼−0.94%×0.07

Aug 6 '25±13.1%▲+1.76%×0.13

Q3 FY25±22.5%▼−5.79%×0.26

Q1 FY26±13.7%▲+4.25%×0.31

May 13 '26±6.5%0.00%×0.00

Q2 FY26—▼−1.71%—

quarterimplied−45%0+45%realized×

Q2 FY26—▼−1.71%—

May '26±6.5%0.00%×0.00

Q1 FY26±13.7%▲+4.25%×0.31

Q3 FY25±22.5%▼−5.79%×0.26

Aug '25±13.1%▲+1.76%×0.13

May '25±14.1%▼−0.94%×0.07

2 older reports

Mar '25±43.7%▼−2.39%×0.05

Jan '25±7.5%▲+1.82%×0.24

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Nov 12 report · est.

Bull2 of 4

9disclosed supplier and customer ties in SEC filingsSEC filings

4tracked funds holding ABUSN-PORT · Aug 31 '26

Bear2 of 4

7 of 7recent reports where the move came in under the options-implied rangeEarnings history

7 of 24of the largest reporting managers cut their stake in the latest quarter13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

Linked exposure

ABUS report session

No linked exposure.

Latest changes

30 daysAll changes

Oct 30impliedImplied move: ±30.3% into Nov 12 earnings (Oct 30 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.